Moderate

Recurrent Clostridioides difficile infection

rCDI · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Recurrent C. difficile infection (symptom return within 8 weeks of treatment) reflects persistent spores and disrupted microbiota. Management favours fidaxomicin, tapered regimens and microbiota restoration (faecal transplant or live biotherapeutics), reserving vancomycin tapers and avoiding unnecessary antibiotics.

Red flags

  • Fulminant disease: hypotension, ileus, toxic megacolon
  • Rising lactate/WCC, falling albumin
  • Abdominal distension with reduced bowel sounds
  • Signs of perforation/peritonitis
  • Severe dehydration/acute kidney injury

Assessment

Differential diagnosis

  • Post-infective irritable bowel / functional diarrhoea
  • Inflammatory bowel disease flare
  • Other infective colitis
  • Reinfection with a new strain
  • Overflow diarrhoea / laxative effect

Investigations

  • Stool toxin EIA plus GDH or PCR (confirm active infection, not colonisation)
  • FBC, renal function, lactate and albumin for severity
  • Abdominal imaging if severe/complicated (toxic megacolon)
  • Review of ongoing antibiotic and PPI use
  • Assess number and timing of prior episodes
  • Exclude alternative causes of diarrhoea

Management

  • Confirm true recurrence with toxin testing (avoid treating colonisation)
  • Assess severity and exclude fulminant disease/toxic megacolon
  • Stop or minimise precipitating antibiotics and review proton-pump inhibitor need
  • For first recurrence, use fidaxomicin or a vancomycin taper-pulse regimen
  • For multiple recurrences, prioritise faecal microbiota transplantation or a licensed live biotherapeutic
  • Consider adjunctive bezlotoxumab to reduce recurrence in high-risk patients
  • Maintain fluid/electrolyte balance and nutrition
  • Institute infection-control measures (isolation, hand hygiene with soap, environmental cleaning)
  • Avoid anti-motility agents in active severe colitis
  • Educate on recurrence risk and prompt re-presentation
  • Plan prophylactic vancomycin during future unavoidable antibiotics in selected patients
  • Follow up to confirm resolution

Drugs & doses

Fidaxomicin 200 mg PO twice daily for 10 days (preferred for recurrence)
Vancomycin oral taper-pulse (e.g. 125 mg four times daily then tapering over weeks)
Bezlotoxumab 10 mg/kg IV single dose (adjunct to reduce recurrence in high-risk)
Faecal microbiota transplantation or licensed live biotherapeutic for multiply recurrent disease

Disposition

Outpatient for mild recurrence; admit for severe/fulminant disease; gastroenterology/ID and FMT service referral.

Complications & pitfalls

  • Toxic megacolon and perforation
  • Fulminant colitis and death
  • Repeated recurrences and malnutrition
  • Protein-losing enteropathy
  • Transmission in healthcare settings

Exam pearls

  • Fidaxomicin reduces recurrence versus vancomycin and is preferred for recurrent disease
  • Faecal microbiota transplantation is highly effective for multiply recurrent CDI
  • Only test and treat symptomatic patients - do not treat colonisation
  • Stop unnecessary antibiotics and PPIs to reduce recurrence
  • Use soap-and-water hand hygiene; alcohol gel does not kill spores

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.